Diabetic retinopathy is a leading cause of acquired visual loss. Current treatment modalities are not effective in all cases and may have side effects. Investigation of the biochemical basis of diabetic retinopathy suggests that future treatments may reverse or halt the progression of diabetic retinopathy, or actually prevent the development of diabetic retinopathy. Pharmacological manipulation of protein kinase C and various growth factors may form the basis of future treaments for diabetic retinopathy.
Introduction
Diabetic retinopathy (DR) remains a significant cause of acquired visual loss in adults worldwide and it is the number one cause of new blindness in the working aged population in western countries, thus leading to substantial medical, social, and financial burdens. 1 In the United States, diabetes mellitus affects over 16 million people, although only half of this number are aware that they have the disease. Similarly, at least 2% of the United Kingdom population is known to have the disease and in both countries DR is the leading cause of new cases of legal blindness in adults between 20 and 70 years of age. 2 Some level of DR is present in 2.5% of the population of the United States (Vision Problems in the US, available from National Eye Institute and Research to Prevent Blindness, 2002 ) and in nearly all diabetic patients with duration of diabetes of 20 years or more. Approximately 25% of patients have the more severe sight-threatening levels of retinopathy. 3, 4 Severe visual loss in patients with diabetes primarily arises from intraocular angiogenesis resulting in proliferative diabetic retinopathy (PDR), while the main cause of moderate visual loss is leakage of retinal vessels resulting in diabetic macular oedema (DME). Since the great majority of patients have type II diabetes and since DME is more common in type 2 disease, more people have visual loss from DME than from PDR. 5 The risk of severe visual loss, defined as visual acuity of 5/200 or worse at two consecutive visits 4 months apart, from PDR is about 60% after 6 years if not treated with laser panretinal photocoagulation (PRP). 6 The risk of moderate visual loss, which is defined as doubling of the visual angle at two consecutive visits 4 months apart, from clinically significant macular edema (ME) is about 33% after 3 years. 7 Current treatment modalities can greatly reduce this visual loss; however, these modalities are not successful in every case and may be associated with significant side effects and complications. Owing to the limitations, potential side effects, and complications of these treatments, significant efforts continue to be directed towards the development of novel, more effective, and nondestructive therapeutic modalities. Investigations into such potential therapies have taken a variety of approaches and include optimization of systemic conditions including blood glucose levels and hypertension, blockade of angiogenic growth factors, blockade of intracellular signalling and pathways utilized by these angiogenic agents, evaluation of naturally occurring endogenous angiogenic inhibitors, evaluation of the role of the extracellular matrix and vitreo-retinal interface, and antioxidants.
Current treatment for DR
Two large multicentre, prospective, case-control studies, the Diabetic Retinopathy Study (DRS) 6 and the Early Treatment of Diabetic Retinopathy Study (ETDRS), 7 provided the evidence that laser photocoagulation reduces the risk of visual loss in DR. Specifically, the DRS demonstrated that PRP reduced the risk of severe visual loss by 50% in eyes with high-risk proliferative diabetic retinopathy (HRC PDR). 6 The ETDRS demonstrated that early detection of the development of such high-risk characteristics of retinal neovascularization and timely PRP reduced the risk of severe visual loss to less than 2%. 7 The ETDRS also defined clinically significant macular edema (CSME) as being ME involving or threatening the centre of the macula and demonstrated that focal or grid laser photocoagulation could reduce the risk of moderate visual loss due to CSME by 50%. 7 The comprehensive nature of this evidence has led to the widespread incorporation of these treatment approaches into standard clinical practice. Laser treatment of eyes at or approaching HRC-DR and/or CSME is the current standard of care. However, laser photocoagulation has potential side effects, including reduction in visual field and nyctalopia arising from the inherent destruction of retinal tissue associated with PRP. Potential complications include damage to other intraocular structures or misplaced burns. Furthermore, the chorioretinal scars associated with laser photocoagulation can enlarge over time, resulting in foveal encroachment or extensive photoreceptor loss, pigment clumping, and vessel attenuation, mimicking that observed in retinitis pigmentosa.
Optimization of glycaemic control and systemic hypertension
Two important multicentre clinical trials, the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), conclusively demonstrated that intensive glycaemic control slows the onset and progression of DR and other vascular complications in both type 1 and type 2 diabetes. [8] [9] [10] A total of 1441 patients with type 1 DM was studied longitudinally in the DCCT for a mean duration of 6.5 years. The mean HbA1c in the intensive therapy group was significantly less than that in the conventional therapy group (7.2 and 9.1%, respectively). 8 Intensive therapy resulted in a 76% reduction in the onset of DR, a 63% reduction in the progression of DR, a 47% reduction in the development of severe nonproliferative or proliferative DR, a 26% reduction in the development of macular edema, and a 51% reduction in the overall need for laser. 8, 11 The disadvantages of intensive insulin therapy included increased episodes of hypoglycaemia and a two times greater occurrence of early initial worsening in retinopathy, which was reversed after 18 months. 12 This reduction in the risk of progression of retinopathy resulting from intensive insulin therapy persisted for at least 4 years after the end of the DCCT trial, despite the fact that 4 years after the end of DCCT the levels of glycaemic control converged for both groups. 9 The multicentre UKPDS study involved 3867 patients with newly diagnosed type 2 DM, who were randomly assigned to intensive therapy (using either sulphonylurea or insulin) or conventional control. 10 The mean HbA1c after 10 years was significantly lower in the intensive therapy group than in the conventional therapy group (7.0 and 7.9%, respectively). Intensive glycaemic control significantly reduced the need for retinal photocoagulation by 29% and resulted in a 17% reduction in the progression of retinopathy, both of which were significant when compared with the conventional treatment group. 13 Similar risk reductions were observed using either sulphonylureas or insulin therapy.
It has been demonstrated that patients with diabetes have a higher prevalence and incidence of systemic hypertension than people without diabetes.
14 Elevated blood pressure (BP) is associated with more severe levels of retinopathy initially, an increased risk of developing any retinopathy, an increased risk of developing more severe levels of retinopathy, and an increased risk of more rapid progression of retinopathy when compared to diabetic patients without hypertension. [15] [16] [17] A recent review of systemic factors influencing DR highlighted that the two main types of epidemiological studies of the relation between DR and hypertension were crosssectional studies and prospective longitudinal studies. Overall, about two-thirds of cross-sectional reports of both type 1 and type 2 diabetic patients over the last 20 years demonstrated an association between DR and hypertension, but this association was weak in elderly type 2 patients. Interestingly, only one of the more recent prospective studies did not demonstrate an association between elevated BP and DR. 18 The UKPDS also demonstrated that elevated BP was an independent risk factor for onset and progression of DR. 19 Of 1148 patients enrolled into this part of the study, 758 patients were assigned to an intensive BP control group and 390 patients were assigned to a less tight control group. A significant BP reduction was achieved Growth factors and protein kinase C inhibitors as novel therapies LP Aiello et al 118 by the intensive group over a median of 8.4 years resulting in a 34% reduction in DR progression and 47% reduction in moderate visual acuity loss, both of which were significantly lower than the reduction seen in patients with moderate BP control. 19 These risk reductions were independent of glycaemic control and were similar, regardless of whether the hypertension was controlled with angiotensin-converting enzyme (ACE) inhibitors or beta blockers.
Recent laboratory studies have suggested a number of mechanisms by which hypertension may increase the risk of developing DR. 20 These mechanisms include hypertension-induced vascular stretching resulting in increased expression of vascular endothelial growth factor (VEGF) and its receptors, 21 and enhancement of retinal endothelial damage. 22 While epidemiological and laboratory studies into the effects and mechanisms of elevated BP in DR are ongoing, there is sufficient evidence available that all diabetic patients should have their BP maintained as low as safely possible.
Blockade of angiogenic factors
Recently, there has been an explosion in knowledge regarding the biochemical processes underlying DR. Particular attention has been focused on the role of growth factors in the pathogenesis of DR. Ironically, Michaelson 23 first proposed the concept of growth factors 50 years ago, and this concept has been elaborated further by subsequent authors. 24 The theory predicts ideal characteristics that a molecule should possess if it truly caused proliferative retinopathy. These characteristics included production of the molecule by the retina, induction by hypoxia, stimulation of neovascularization, and secretion into and diffusion throughout the eye. Endothelial cells would be expected to have high-affinity receptors for such a molecule, intraocular levels should be elevated during proliferation, reduced after treatment or during quiescence, and blockage of its effects should suppress hypoxia-induced neovascularization. Demonstration of these criteria in a candidate growth factor provides strong evidence that it could serve as a major mediator of proliferative retinopathy.
Numerous candidate molecules have been investigated as potential mediators of diabetic retinal vascular complications. Those that have received considerable evaluation include basic fibroblastic growth factor (bFGF), growth hormone (GH), 25, 26 insulin-like growth factor -1 (IGF-1), 27, 28 connective tissue growth factor (CTGF), 29 prostacyclin-stimulating factor (PSF), 30 hepatocyte growth factor (HGF), [31] [32] [33] and vascular endothelial growth factor (VEGF). 34, 35 bFGF, GH, IGF-1, and CTGF are growth factors that do not fulfil all of the Michaelson criteria, but probably have either synergistic or permissive roles in PDR. The expression of these permissive or synergistic growth factors may be regulated by a complex interaction of different growth factors, which is still not fully understood. For example, bFGF acts synergistically with VEGF, 36 but unlike VEGF is not primarily responsible for ischaemia-induced retinal neovascularization. 37 Another example is CTGF, which may have a role in the pathogenesis of retinal fibrosis, matrix deposition, and angiogenesis. Retinal vascular endothelial cells express this molecule and VEGF appears to increase CTGF gene expression in endothelial cells via VEGF receptors and the activation of PI-3 kinase but not protein kinase C (PKC) or RAS pathways. 38 Another factor, PSF, stimulates endothelial cell synthesis of prostacyclin PG12, a vasoactive prostaglandin, which may be responsible for the biphasic changes in retinal blood flow seen in diabetes. 39 HGF has attributes consistent with a mediator of proliferative retinopathy, but its role is still under investigation. HGF is a pleiotropic molecule and its receptor, c-Met, like that of VEGF's KDR receptor, is a transmembrane tyrosine kinase that is autophosphorylated in response to HGF binding. 40, 41 HGF acts as a mitogen in many cells, including retinal endothelial cells, which are sensitive to the effects of HGF at physiologically relevant concentrations. 42 There is evidence that the HGF/cMet signal transduction cascade involves PI3 kinase, PKC, and MAP kinase pathways, and HGF in vivo can increase retinal permeability.
VEGF is the most extensively studied molecule that fulfils all of the Michaelson criteria. For this reason, it is a principal focus of novel treatments for PDR, other proliferative retinopathies, and systemic diseases characterized by abnormal angiogenesis. VEGF is a highly conserved glycoprotein with four isoforms, the two smaller of which are freely diffusible within the eye. 43 VEGF is produced by many intraocular cells including pigment epithelial cells, pericytes, and endothelial cells. 44, 45 Autophosphorylating tyrosine kinase VEGF receptors (KDR receptor) have been identified on retinal microvascular endothelial cells at high densities. 46 VEGF is primarily an endothelial mitogen, 43, 47, 48 and animal models [49] [50] [51] [52] [53] and clinical studies 34, [54] [55] [56] have demonstrated hypoxia-induced retinal VEGF concentration elevations leading to retinal neovascularization. Furthermore, intraocular levels of VEGF decrease after adequate treatment of retinal neovascularization with laser photocoagulation. Increased vascular permeability is another hallmark of intraocular neovascularization, and direct evidence now exists that physiologic concentrations of VEGF increase retinal vascular permeability as measured by vitreous
Eye fluorophotometry and that this increased permeability is suppressed by VEGF inhibitors. 57 Biochemically, hypoxia-induced increases in adenosine can bind to the adenosine A 2 receptor and potentially mediate hypoxia-induced VEGF expression, while synergistically inducing endothelial migration (through A 2 receptors) and capillary tube formation (through A 1 and A 2 receptors). 58, 59 Reactive oxygen intermediates also stimulate VEGF mRNA and protein production, an effect that is dose-dependent and blocked by antioxidants. 60 Experimental inhibition of VEGF production or binding to its receptor results has an antiproliferative effect demonstrated using a number of different agents in several different animal models. In a primate model, iris neovascularization from laser-induced retinal vein occlusion was reduced by VEGF-neutralizing monoclonal antibody. 61 In a mouse neovascularization model, both chimeric proteins (which sequestered VEGF) 62 and antisense oligonucleotides (which suppress VEGF transcription) reduced retinal new vessel formation by 40-100%. 63 It has also been demonstrated in a murine model of retinal neovascularization that inhibition of VEGF receptor kinase activity completely blocks retinal neovascularization. 64 
Blockade of signal transduction pathways
The signal transduction mechanism initiated by VEGF binding to its receptors on retinal endothelial cells is characterized by increased tyrosine phosphorylation of phospholipase g (PLC g) and PI-3 kinase. 65 PLC g activation leads to increases in diacylglycerol and subsequent activation of classical forms of PKC, especially the bII and d isoforms. 66 Experimental work has demonstrated that selective inhibition of the PKC b isoform prevents VEGF-mediated cell growth in vitro, 57 while inhibition of the PKC a isoform stimulates growth. 57 Furthermore, inhibition of PKC b in vivo reduces ischaemic retinal neovascularization in an animal model. 67 Both intravitreal and oral forms of a PKC b inhibitor have been shown to block VEGF-induced increases in retinal vascular permeability in animals and to normalize changes in retinal blood flow characteristically induced by DR in both animals and humans.
68 Recent studies also demonstrate that PKC inhibition can normalize diabetesinduced retinal vascular permeability in animals, even after diabetes has been established for as long as 1 month prior to initiating therapy (Aiello, unpublished data).
Recent data derived from transgenic mouse models provide substantial support for the hypothesis that PKC b is involved in mediating retinal neovascularization and that inhibition of this molecule may have therapeutic benefit. Transgenic animals were derived where PKC b2 is overexpressed in the vasculature using a pre-proendothelin promoter. When these animals experience retinal ischaemia, the retinal neovascular response is greatly accentuated, suggesting that PKC b expression plays a significant role in this response. More important information from a therapeutic standpoint is derived from animals where the PKC b gene has been removed, resulting in animals with no PKC b (PKC b knockout). When PKC b knockout mice are exposed to similar retinal ischaemia, retinal neovascularization is reduced. 69 These data and the safety and pharmocologic results of PKC b inhibitors to date have supported the undertaking of two Phase II/III studies and a large Phase III study. These two Phase II/III studies have just recently been completed and data analysis should begin soon. These studies evaluate whether an orally administered PKC b selective inhibitor is effective in preventing the progression of nonproliferative DR to PDR or in preventing progression (or inducing regression) of DME. To date, the safety profile of the medication has been excellent and no clinically significant side effects associated with the compound have been appreciated.
Endogenous inhibitors of angiogenesis
Neovascularization probably results from an alteration of the normal balance between natural promoters and natural inhibitors of angiogenesis in favour of proangiogenic molecules. A number of molecules have been identified as endogenous inhibitors of angiogenesis including endostatin, angiostatin, thrombospondin-1, and pigment epithelium-derived factor (PEDF). Of these natural antiangiogenic agents, PEDF has become a major focus of attention. 70 PEDF is a 50-kDa molecule, originally purified from human retinal pigment epithelial cells, which contains protein sequences homozogous to the serine protease inhibitor (SERPIN) family of molecules. 70 PEDF, however, does not inhibit serine proteases. Recent experimental work has shown that PEDF can inhibit VEGF, bFGF, and other angiogenic factors in vitro, an effect reversed by antibody neutralization of PEDF. 70 The amount of PEDF produced by retinal cells was positively correlated with oxygen concentrations in animal models, while hypoxia-induced retinal neovascularization resulted in a 10-fold increase in the VEGF/PEDF ratio in a rat model. 71 PEDF has also been shown to inhibit hypoxia-induced angiogenesis in a mouse model of retinal neovascularization. 64, 72 As understanding of the mechanism of action of PEDF increases, future novel treatments of DR might utilize synthetic versions of this molecule or stimulate similar intracellular pathways to prevent the onset of intraocular angiogenesis.
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Alterations of the extracellular matrix and vitreo-retinal interface
Remodelling of the extracellular matrix, which enables endothelial cells to migrate towards an angiogenic stimulus, is a component of proliferative retinopathies. Two main groups of molecules are involved in this migration of endothelial cells. The first of these are the matrix metalloproteinases (MMPs), a family of zincbinding, calcium-dependent enzymes that selectively degrade the extracellular matrix. MMPs are inhibited naturally by a separate group of multifunctional proteins known as tissue inhibitors of metalloproteinases (TIMP). A balance between MMPs and TIMPs probably preserves tissue integrity in normal eyes, as evidenced by expression of MMP-1 (interstitial collagenase) and TIMP-2 in nondiseased retina. 73 Increased levels of MMP-9 (gelatinase B) have been demonstrated in the vitreous of eyes with PDR, while fibrovascular membranes from eyes with PDR stain for MMP-1, MMP-2 (gelatinase A), MMP-3 (stromelysin-1), MMP-9, TIMP-1, TIMP-2, and TIMP-3. Release of both MMPs and TIMPs may be under the control of cytokines produced by a number of ocular cells, including endothelial cells, although the exact mechanisms are not fully understood. 74, 75 Future novel therapies for proliferative retinopathies, including DR, may be directed at manipulating the intraocular balance between MMPs and TIMPs. 76 Integrins are another group of molecules that mediate migration of vascular endothelial cells through the extracellular matrix. These are cell-surface adhesion molecules that interact with numerous components of the extracellular matrix. 77 Two integrins in particular, 2vb3 and 2vb 5 , have been studied with regard to intraocular neovascularization and appear to mediate two separate cytokine-dependent angiogenesis pathways. 77 Integrin 2vb3 mediates one pathway induced by bFGF or tissue necrosis factor a (TNFa), 78 and promotes growth by suppression of apoptosis and upregulation of angiogenesis promoter p53. 79 Integrin 2vb 5 mediates a second pathway induced by VEGF or transforming growth factor a (TGFa), which is PKC dependent. 78 Both integrins 2vb3 and 2vb 5 are detectable in fibrovascular membranes of eyes with PDR. 77 Systemically administered cyclic peptides, which block the integrins, prevent retinal angiogenesis in a mouse model, 77 and can inhibit hypoxia-induced retinal neovascularization. 80 Inhibition of integrins 2vb3 and 2vb 5 by such peptides or molecules that mimic their action could provide another target for future novel therapies for DR and other proliferative retinopathies.
Some of the complications of PDR are a result of the interaction between the vitreous and retinal surface new vessels. Intraocular injections of enzymes such as plasmin and chondroitinase to cleave structural components of the vitreous body or inner retinal surface have been demonstrated to create posterior vitreous detachment (PVD) in animals [81] [82] [83] and human eyes. 84 The ability to create a PVD when required would be advantageous in diabetic patients as attached vitreous provides scaffolding which can support retinal neovascularization. Prophylactic removal of such support would also prevent vitreous traction on retinal new vessels, potentially reducing the risk of vitreous haemorrhage and tractional retinal detachment.
A similar approach to speed resolution of vitreous haemorrhage is already approved in Mexico and pending evaluation in the US.
Antioxidants
Another possible novel preventative oral therapy for DR is vitamin E. Studies of vitamin E in diabetic animals have shown reduced retinal DAG levels, normalized PKC-b activation, normalized retinal blood flow, and restored nitric oxide-mediated endothelium-dependent relaxation. 85, 86 A recent clinical study demonstrated that short-term, high-dose oral vitamin E therapy normalized retinal and renal haemodynamics in diabetic patients with disease of less than 10 years duration despite no change in glycaemic control. 87 Whether these changes will eventually result in suppression of DR awaits a prospective, randomized clinical trial. Since overdosage with vitamin E can potentially result in toxicity, high doses of vitamin E should not be advocated until results of appropriate clinical trials are known.
Changing the treatment paradigm for novel therapies
At present, PRP is indicated for eyes with HRC PDR and should be considered for eyes approaching this stage. Macular focal laser photocoagulation is indicated for patients with CSME. This treatment paradigm balances the threat of visual loss against the potential damaging effects of laser therapy. Treatment is applied at stages of DR where the underlying biochemical processes are already advanced. In some instances, these changes may be irreversible, as evidenced by cases that fail to respond to laser therapy despite timely intervention.
Novel therapies that manipulate the balance between proangiogenic molecules like VEGF and antiangiogenic molecules like PEDF have significant and partially opposing implications for the microvascular and macrovascular complications of diabetes. 88 In microvascular complications such as DR and diabetic nephropathy, production of VEGF leads to damaging neovascularization and increased retinal permeability. In For DME, intravitreal steroid sustained release implant (fluorcinolone acetonide), intravitreal steroid biodegradable sustained release implant (dexamethasone), and intravitreal aptamer VEGF inhibitor (macugen) are currently undergoing clinical trial for ocular complications of diabetes. Additionally, studies using intravitreal steroid injections (triamcinolene acetonide) and intravitreal humanized anti-VEGF antibody fragment (rhuFab V2) to treat DMF are in the planning stage.
For nonocular administration approaches, Phase 1/2 clinical trials of an oral, once daily PKC b inhibitor (LY333531) to treat nonproliferative and proliferative DR and DME have been recently completed. A Phase III trial is ongoing. Trials with an intramuscular injection of a growth hormone antagonist (Sandostatin) to treat PDR and an oral COX2 inhibitor (Celebrex) to treat DME are also ongoing.
With the arrival of novel therapies for the treatment of DR, monitoring the level of DR will be of paramount importance to determine the need for treatment, when to discontinue treatment, and whether to reinstitute treatment. Novel therapies with less-damaging side effects than laser therapy might be initiated at earlier stages of DR when the underlying processes are beginning and advanced tissue damage is minimal. Since the stages of DR and DME most amenable to treatment are usually asymptomatic, patients will need to be identified by regular comprehensive examinations. Novel therapies might also be used as adjuvants to laser therapy, either before laser, simultaneously with laser, or in cases where laser fails. Similarly, novel therapies might be used before or after vitrectomy or might be implanted intraocularly during vitrectomy.
Conclusion
Laser photocoagulation is the current standard of care for the treatment of sight-threatening DR. Use of this therapy is based on evidence from prospective, multicentre, randomized studies performed and analysed over the past 30 years. Laser photocoagulation is directed towards inducing the regressing of existing neovascularization or ME rather than treating the underlying biochemical processes of DR. In addition, laser photocoagulation has a number of significant side effects and potential complications. Increased understanding of the biochemical pathways underlying DR has resulted in the identification of numerous potential novel therapies. Currently, the most promising among these are inhibition of intraocular growth factors (such as VEGF), inhibition of intracellular signalling cascades (such as PKC b inhibitors), use of endogenous inhibitors (such as PEDF), and prophylactic treatment with antioxidants. In the near future, it is possible that novel therapies may result in alterations of the current treatment paradigm for DR. Treatments directed against the biochemical pathways underlying DR may best be initiated before sightthreatening levels of retinopathy are reached so as to provide optimal benefit. As early stages of DR are usually asymptomatic, patients will need to undergo regular examinations to identify the need for treatment. Overall, with the diverse array of novel therapeutic approaches currently under investigation, it is likely that the next decade will be marked by exciting new treatment options providing new benefits to our patients with diabetes and diabetic eye disease.
